A Secret Weapon For Nemifitide diTFA
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Primary trial aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis